Can a second diuretic boost recovery from heart failure?

NCT ID NCT06166654

Recruiting now Disease control Sponsor: Johannes Grand Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial investigates whether adding either metolazone or acetazolamide to standard loop diuretics helps adults hospitalized with acute heart failure and fluid overload. Participants are randomly assigned to one of three treatment arms, and the study tracks days alive and out of the hospital within 30 days. The goal is to find the most effective strategy for reducing congestion and improving recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acetazolamide or metolazone added to standard loop diuretics
What this could lead to: If successful, this could identify a more effective diuretic combination to help people with acute heart failure recover faster and spend less time in the hospital.
What could go wrong: This is a phase 4 trial, but results may vary by patient. Risks include potential side effects from the added diuretics, such as kidney issues or electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE HEART FAILURE

Contacts and locations

Locations

Aarhus university Hospital
RECRUITING

Aarhus, 2650, Denmark
Amager-Hvidovre Hospital
RECRUITING

Hvidovre, Capital Region of Denmark, 2650, Denmark
Bispebjerg Hospital
NOT_YET_RECRUITING

Copenhagen, 2400, Denmark
Herlev-Gentofte hospital
RECRUITING

Copenhagen, 2730, Denmark
Zealand University Hospital
RECRUITING

Roskilde, 2650, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.